S. Kroll

Articles

Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data

J. P. Leonard;A. D. Zelenetz;J. M. Vose;J. A. Radford;R. L. Wahl;A. Rohatiner;S. Kroll;R. Stagg;K. Nadeau;N. Valente;M. S. Kaminski

March 1st 2001

Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses

Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology

J. M. Vose;A. D. Zelenetz;A. Rohatiner;S. Knox;R. Stagg;S. Kroll;G. Tidmarsh;M. S. Kaminski

March 1st 2000

Iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-

Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience

M. S. Kaminski;O. W. Press;T. A. Lister;N. K. Valente;S. Kroll;G. Tidmarsh

March 1st 2000

Tositumomab and iodine -131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of low-grade or transformed, low-grade non-Hodgkin’s lymphoma (NHL).